BiotechTubeBiotechTube
Home/Silence Therapeutics/David Horn Solomon
DH

David Horn Solomon

Chief Financial Officer

Silence Therapeutics

Therapeutic Areas

CardiovascularHematologyMetabolicRare Diseases

Silence Therapeutics Pipeline

DrugIndicationPhase
Zerlasiran (SLN360)Cardiovascular Risk Reduction (Elevated Lp(a))Phase 2
SLN124Polycythemia Vera & Myeloproliferative NeoplasmsPhase 1
Dapirolizumab PegolSystemic Lupus Erythematosus (SLE)Phase 3
AZD8233 (AstraZeneca)Cardiovascular, Metabolic (PCSK9 target)Phase 1

Leadership Team at Silence Therapeutics

CT
Craig Tooman
President and Chief Executive Officer
DG
Dr. Giles Campion
Senior Vice President, Head of R&D and Chief Medical Officer
DM
Dr. Mark Rothera
Former President and Chief Executive Officer
KM
Kristine M. Ball
Senior Vice President, Corporate Development and Strategy
MR
Mark R. Chin
Senior Vice President, General Counsel
JH
Joanne Harrison
Senior Vice President, Human Resources
DM
Dr. Mark R. Penny
Senior Vice President, Non-Clinical Development
DM
Dr. Mark J. P. van Ool
Senior Vice President, Technical Operations
View full Silence Therapeutics profile